Cocrystal Pharma, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held on June 9, 2020. Cocrystal Pharma, Inc. is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): All five nominees were elected to one-year terms. Notably, Dr. Anthony Japour received the highest support with 25,812,820 votes for, while Mr. Steven Rubin received 11,456,705 votes for and 14,471,689 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2020. The vote was 37,659,301 for, 1,163,991 against, and 2,319,777 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of votes withheld for Mr. Steven Rubin compared to other directors.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the definitive proxy statement filed on April 28, 2020, for detailed biographies of the elected directors and the rationale for the auditor appointment.